Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07619339 · ClinicalTrials.gov registry record · Phase 1
A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT07619339: Recruiting Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07619339 is a Phase 1 study that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07619339, a Phase 1 study, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The researchers are doing this study to find out whether the combination of tepotinib and ivonescimab is a safe and effective treatment for people with non-small cell lung cancer (NSCLC) that is positive for METex14 skipping. The researchers will test up to two different doses of tepotinib in combination with ivonescimab to find the best dose of tepotinib that causes few or mild side effects in participants.
Primary Outcome
The primary objective of the dose finding phase is determination of the recommended dose expansion dose using a standard 3+3 design based on dose-limiting toxicities (DLT). DLT definition: any grade ≥ 3 immune-related adverse event attributable to synergistic combinatorial toxicity from tepotinib and ivonescimab.
Interventions
- DRUG Ivonescimab
- DRUG Tepotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-05-27 |
| Est. Completion | 2029-05 |
| Phase | Phase 1 |
What NCT07619339 shows while recruiting
NCT07619339 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which Ivonescimab is the first listed.
NCT07619339 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07619339 about?
NCT07619339 is a clinical study titled "A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer". The researchers are doing this study to find out whether the combination of tepotinib and ivonescimab is a safe and effective treatment for people with non-small cell lung cancer (NSCLC) that is positive for METex14 skipping. The researchers will test up to two different doses of tepotinib in combin...
What is the current status of trial NCT07619339?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2026-05-27. Estimated completion is 2029-05.
What interventions are being tested in trial NCT07619339?
The interventions under investigation include: Ivonescimab (DRUG), Tepotinib (DRUG).
Who is sponsoring clinical trial NCT07619339?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07619339's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI